Oncology Drugs

With a new cancer drug showing promise but cash reserves dwindling, Citius Pharma's CEO faces a critical test: convincing investors the pipeline is worth the risk.

The prestigious Prix Galien awards debut in Seoul, cementing South Korea's status as a life sciences leader and spotlighting a wave of homegrown innovation.

A biotech startup is targeting a hidden cause of chemo resistance. An AI firm claims it can predict a drug's success. Their deal is a major market signal.

As it launches a pivotal trial for its MYC inhibitor, Persevere Therapeutics adds a seasoned CEO to its board, signaling a sharp focus on funding and strategy.

BioLineRx secures crucial funds for its cancer drugs, but at a cost. We dissect the deal, the shareholder dilution, and what it reveals about biotech financing.

A new FDA approval for Roche's HER2 tests paves the way for a powerful new drug, offering hope to patients with aggressive gastroesophageal adenocarcinoma.

Avenzo Therapeutics' new CHRO hire is more than a personnel move; it's a critical piece of a master plan for a public debut and oncology market disruption.

PMV Pharma's rezatapopt shows remarkable results for a tough cancer by reactivating a key defense. A deep dive into the science, finances, and patient hope.

Fannin Partners secures key grants to advance its Raptamer therapy for a rare pediatric cancer, highlighting a funding model vital for high-risk innovation.

Caribou Biosciences reports impressive clinical data for its allogeneic CAR-T therapies, but the path to broader patient access hinges on a critical hurdle: funding.

With a cash runway to 2029 and a novel cancer drug nearing key data, NuCana signals quiet confidence in a high-stakes race to treat resistant melanoma.

Inhibrx Biosciences lands a massive new loan to fuel its promising cancer drug trials, but rising costs and a wider net loss paint a high-stakes picture.

Rigel's VEPPANU is the first FDA-approved PROTAC, a new class of drug that destroys disease proteins. This is the story behind the science and the numbers.

Curis secures a crucial, albeit small, $5.6M funding lifeline. Will it be enough to push its promising cancer drug through trials before the clock runs out?

With pivotal lung cancer data imminent, ArriVent BioPharma juggles a high-risk, high-reward strategy, betting its future on a novel drug and a new wave of ‘smart bomb’ therapies.

A new partnership is bringing advanced, U.S.-based manufacturing to a rare cancer drug, aiming to solve daily patient challenges and bolster national supply chains.

Amid a selective biotech market, Rakovina Therapeutics' oversubscribed placement highlights investor belief in its AI-powered strategy for next-gen cancer drugs.

A biotech's new funding offers a glimmer of hope for a novel cancer therapy, but a look at the books reveals a desperate race against time and capital.

BridgeBio Oncology is doubling down on a costly strategy, betting that combining its novel drugs is the key to defeating hard-to-treat RAS-driven cancers.

With pivotal data imminent for two cancer drugs and a fortified balance sheet, SELLAS is at a crucial inflection point. Can it deliver on its promise?